Illumina

Truveta is a health data platform that collaborates with physicians, life science researchers, and others in the healthcare community to compile medical records from partner organizations, connecting treatments with outcomes and various health factors. The platform aggregates data across multiple healthcare systems to identify and harmonize medical information, enabling researchers and clinicians to analyze treatment effectiveness and support informed decision making across patient care.

Cache is a biotechnology company focused on developing a groundbreaking wet operating system designed for the storage, access, and computation of biomolecules at scale. By ensuring the integrity and fidelity of nucleic acids from various sources, Cache enables researchers and partners to accelerate molecular pathology research and gain insights into life sciences. This innovative approach facilitates the analysis of biomolecules, thereby unlocking new precision medicine applications and enhancing the capacity for understanding biological data. Ultimately, Cache aims to make both digital and biological data universally accessible and sustainable, eliminating the need for data deletion or disposal.

Mantra Bio, Inc. is a biotechnology company focused on developing targeted therapeutics through its proprietary platform for engineering Targeted Exosome Vehicles (TEVs). Founded in 2016 and based in San Francisco, California, the company utilizes its REVEAL platform, which integrates computational biology, wet lab techniques, and automation. This innovative approach leverages the diversity of exosomes to design and optimize therapeutics aimed at various tissue and cellular targets. Mantra Bio has also established a scalable biomanufacturing process to ensure the reproducibility and high purity of its next-generation therapeutics, enabling medical practitioners to address challenging diseases effectively.

Neurolytic Healthcare Ltd. is a medical technology company based in Oxford, United Kingdom, specializing in the design, development, and manufacture of digital and genomic-based diagnostic tools and medical devices for migraine and related neurological disorders. Founded in 2016, the company focuses on personalized medicine by integrating genetic and biomarker data to enhance diagnosis and assist clinicians in determining optimal treatment strategies. Its product offerings include a diagnostic support tool, a pharmacogenetic test, and a mobile application designed to predict migraine events. By leveraging artificial intelligence, Neurolytic Healthcare aims to provide genomics-driven diagnostics and personalized treatment recommendations, helping patients find effective treatments while minimizing side effects and reducing the trial-and-error approach often associated with neurological care.

IDbyDNA, Inc. is a biotechnology company focused on developing metagenomics technologies for the precise identification of infectious diseases. Founded in 2014 and based in Salt Lake City, Utah, the company offers its proprietary platform, Explify, which aids laboratories in detecting pathogens through a streamlined workflow. IDbyDNA provides a range of testing services, including respiratory and research services, primarily catering to hospitals, reference labs, clinical research organizations, and the biopharmaceutical industry. By integrating computational biology and artificial intelligence into its offerings, the company enhances the accuracy of nucleic acid-based microorganism detection, enabling healthcare providers to deliver comprehensive infectious disease profiles. IDbyDNA aims to improve diagnostic and treatment practices in response to the growing challenge of infectious diseases, thereby reducing related morbidity and mortality.

Founded in 1999, SomaLogic specializes in the discovery, development, and commercialization of life science research tools and clinical diagnostic products centered around its proprietary SOMAmer/SOMAscan technology. This platform enables protein measurement at scale, facilitating biomarker discovery for various diseases, drug development, and clinical diagnostics.

Concr is a mission-driven techbio company that uses established methods from astrophysics to predict patient outcomes and treatment response to cancer therapies. The approach enables iterative learning from fragmented data across the drug development and clinical journey, producing accurate multi-modal tumor models without relying on large, homogeneous datasets. Its cloud-native platform FarrSight supports computational simulation of clinical trials, prediction of therapeutic response and biomarkers, and standard bioinformatics analyses. Headquartered in London with a wholly owned subsidiary in Brisbane, Concr provides a cloud-based system that identifies optimal treatments for individuals, reduces resistance, and offers patient-specific progression insights and evidence-based treatment plans to guide proactive therapy.

GRAIL focuses on developing technologies for early cancer detection. Founded in 2016, the company specializes in a pan-cancer screening test that measures circulating nucleic acids in blood using high-intensity sequencing.

Enancio SAS, founded in 2017 and based in Cesson-Sévigné, France, specializes in developing software that focuses on genomic data compression. The company's flagship product, Lena, enhances the speed and efficiency of Next Generation Sequencing (NGS) analyses while simultaneously reducing storage costs and minimizing internal network traffic. Enancio's solutions are designed to maintain data integrity, making them a valuable addition to the genomic informatics landscape. As of July 2020, Enancio operates as a subsidiary of Illumina, Inc., thereby complementing Illumina's suite of informatics offerings.

Bluebee is a prominent provider of high-performance genomics solutions, specializing in a cloud-based platform designed for the efficient processing of large volumes of genomic data. This platform addresses the challenges faced by research and clinical laboratories in the rapidly evolving landscape of genetic analysis, particularly with the advent of next-generation DNA sequencing technology. By offering a solution that enhances data processing speed, deep analytics, and flexibility, Bluebee enables healthcare institutions to implement whole genome-based diagnostics more effectively. The company's innovative approach allows for cost-effective genetic screening, supporting the development of new diagnostics and therapies in healthcare while maintaining clinical-grade security and user convenience.

Founded in 2008, Ginkgo Bioworks designs, engineers, and licenses organisms for various applications. It discovers molecules for flavors, sweeteners, cosmetics, crops, pharmaceuticals, and generates probiotic bacteria for health benefits. The company serves markets such as cultured ingredients, carbon mitigation, probiotics, and natural product discovery.

GRAIL focuses on developing technologies for early cancer detection. Founded in 2016, the company specializes in a pan-cancer screening test that measures circulating nucleic acids in blood using high-intensity sequencing.

Edico Genome Inc. is a biotechnology company specializing in bioinformatics solutions for DNA analysis. Founded in 2013 and based in La Jolla, California, the company develops the DRAGEN bio-IT processor, a sequencing application-specific integrated circuit that facilitates efficient analysis of next-generation sequencing data. This platform employs a field-programmable gate array to accelerate genome pipeline algorithms, including BCL conversion, mapping, alignment, and variant calling. By integrating its technology directly into sequencing instruments and bioinformatics servers, Edico Genome enables healthcare institutions to effectively identify connections between DNA sequence variations and human diseases. In 2018, Edico Genome became a subsidiary of Illumina, Inc.

Helixis, Inc. is a company that develops low-cost molecular diagnostic products.

Helix is a leading population genomics company that operates at the intersection of clinical care, research, and genomics. Its comprehensive platform enables healthcare systems, life sciences companies, and payers to advance genomic research and integrate genomic data into clinical care.

Prospect Bio is a synthetic biology company based in Brisbane, California, that specializes in developing biosensors for the detection of small molecules. These biosensors utilize living cells to perform complex chemical measurements, offering a cost-effective and scalable alternative to traditional testing methods that often rely on expensive and slow laboratory equipment. By addressing the need for improved testing solutions driven by regulatory demands, quality control, and supply chain concerns, Prospect Bio aims to transform testing processes across various industries. The company collaborates with a diverse array of partners, including major players in the wine industry, agriculture, prenatal diagnostics, and biotechnology. Its innovative approach combines microbial biotechnologies with automation and computational tools, enabling rapid biosensor and pathway discovery for medical research and other applications.

Vitagene, Inc. is a health technology company that utilizes genomic science and advanced technology to deliver personalized healthcare solutions. Founded in 2014 and based in San Francisco, the company offers a DNA-based personalization platform that helps physicians provide data-driven care. Vitagene's algorithm generates tailored supplement regimens and analyzes extensive patient data, including genetics, blood work, and lifestyle factors, to create customized nutritional plans. Additionally, the company produces DNA health test kits and at-home COVID-19 saliva test kits. It also provides comprehensive health and ancestry reports that encompass diet, exercise, and supplementation insights, ensuring that individuals receive recommendations that align with their specific health needs and goals.

Conexio Genomics, established in 2002 and headquartered in Fremantle, Australia, is a life sciences company specializing in genetic sequencing and mutation detection. It offers products such as Assign SBT and SBT Resolver for high-resolution sequencing and genotyping, and Assign-ATF for automated DNA sequence mutation detection. The company's solutions are used in various applications, including matching patients and donors for bone marrow or cord blood transplants. Conexio Genomics is currently a subsidiary of CareDx.

GRAIL focuses on developing technologies for early cancer detection. Founded in 2016, the company specializes in a pan-cancer screening test that measures circulating nucleic acids in blood using high-intensity sequencing.

Helix is a leading population genomics company that operates at the intersection of clinical care, research, and genomics. Its comprehensive platform enables healthcare systems, life sciences companies, and payers to advance genomic research and integrate genomic data into clinical care.

GenoLogics, Inc. is a software development company that specializes in laboratory information management systems to enhance the diagnosis and treatment of diseases. Founded in 2002 and headquartered in Victoria, Canada, with an additional office in Redwood City, California, GenoLogics offers its BaseSpace Clarity LIMS, which supports research and clinical laboratories by tracking samples throughout the testing process. This platform facilitates improved accuracy, cost reduction, and quality maintenance. The company focuses on translational medicine and systems biology, providing solutions that enable integration across multiple laboratories and enhance biomedical research efforts. As of August 2015, GenoLogics operates as a subsidiary of Illumina Inc.

Founded in 2013, Twist Bioscience specializes in manufacturing and selling synthetic DNA-based products. Its innovative silicon-based DNA Synthesis Platform enables rapid, precise, high-throughput synthesis of DNA, serving customers in healthcare, agriculture, industrial chemicals, and data storage sectors.

Founded in 2013, Human Longevity is a genomic-based health intelligence company headquartered in San Diego, California. It combines the largest database of genomic and phenotypic data with machine learning to drive discoveries and empower proactive healthcare. The company's core offerings include the HLI Health Nucleus, which uses whole-genome sequence analysis and advanced clinical imaging to deliver comprehensive personal health insights.

NextBio is a privately owned software company based in Cupertino, California, co-founded in 2004 by Saeid Akhtari, Ilya Kupershmidt, and Mostafa Ronaghi. The company offers a platform designed for life science researchers to efficiently search, discover, and share knowledge across both public and proprietary data. Its ontology-based semantic framework interconnects diverse data types, including gene, tissue, disease, and compound information, creating a unified searchable environment. This sophisticated platform integrates data from various organisms and research areas, enabling researchers to formulate and test hypotheses with ease. The enterprise version of NextBio's platform is utilized by prominent pharmaceutical companies such as Merck and Johnson & Johnson, allowing the integration of proprietary data with public datasets. Researchers leverage NextBio to enhance their ability to identify significant prognostic and predictive molecular signatures in their studies. The company has garnered recognition, including the Frost & Sullivan North American Life Sciences Customer Value Enhancement Award in 2008, and has attracted over 1,500,000 visitors since its launch.

Advanced Liquid Logic, Inc. is a company established in 2004 by Dr. Michael Pollack and Dr. Vamsee Pamula, who serve as co-CTOs. The company specializes in developing microfluidic devices tailored for liquid handling applications, offering innovative lab-on-a-chip solutions that can be programmed for diverse assay protocols, including immunoassays, polymerase chain reaction (PCR), clinical chemistry, and sample preparation. The team comprises a multidisciplinary group of scientists, engineers, and product developers dedicated to addressing unmet challenges in laboratories and clinics. Under the leadership of CEO Richard West, who has extensive experience in business and product development management, Advanced Liquid Logic aims to enhance workflow efficiency and effectiveness in scientific research and medical diagnostics.

Moleculo is a biotechnology company specializing in innovative DNA sequencing technologies. It has created a novel sequencing method that delivers long and accurate reads, significantly enhancing the efficiency and precision of various DNA sequencing applications. This advancement allows clients to explore a broader range of applications within genomic analysis, positioning Moleculo as a key player in the biotechnology sector focused on improving genomic tools and methodologies.

Verinata Health is a company dedicated to improving maternal and fetal health through the development of non-invasive tests designed for the early identification of fetal chromosomal abnormalities. Utilizing proprietary technologies, Verinata focuses on analyzing cell-free DNA in maternal blood to provide pregnant women with a safe, accurate, and definitive assessment of fetal aneuploidy. This approach aims to alleviate the anxiety associated with traditional multi-step prenatal screening methods, which often have high false-positive rates and can yield confusing results. By offering a single blood draw test, Verinata seeks to fulfill the recommendations for first trimester aneuploidy risk assessment, thereby enhancing the overall experience for expectant mothers. The company is actively conducting a prospective, blinded pivotal study to validate the sensitivity and specificity of its first prenatal test on a large scale, with results anticipated in the near future.

BlueGnome Limited specializes in genetic diagnostic solutions aimed at screening for chromosomal abnormalities. Founded in Fulbourn, United Kingdom, the company focuses on advancing the field of genetic testing to improve healthcare outcomes. In 2012, BlueGnome was acquired by Illumina, a leader in genomic sequencing and analysis, which allowed it to enhance its capabilities and expand its impact in the genetic diagnostics market.

GenoLogics, Inc. is a software development company that specializes in laboratory information management systems to enhance the diagnosis and treatment of diseases. Founded in 2002 and headquartered in Victoria, Canada, with an additional office in Redwood City, California, GenoLogics offers its BaseSpace Clarity LIMS, which supports research and clinical laboratories by tracking samples throughout the testing process. This platform facilitates improved accuracy, cost reduction, and quality maintenance. The company focuses on translational medicine and systems biology, providing solutions that enable integration across multiple laboratories and enhance biomedical research efforts. As of August 2015, GenoLogics operates as a subsidiary of Illumina Inc.

Oxford Nanopore Technologies Limited is a biotechnology company specializing in the development and commercialization of nanopore-based sequencing technology for the analysis of DNA, RNA, proteins, and small molecules. Its innovative product lineup includes the portable MinION device, the benchtop PromethION, and the GridION system, all of which enable real-time data streaming and scalable sequencing for a variety of applications in scientific research, personalized medicine, environmental monitoring, and agriculture. The Flongle offers smaller, on-demand sequencing solutions, catering to users requiring rapid insights. Operating in over 80 countries, Oxford Nanopore's technology is designed for accessibility and ease of use, featuring straightforward library preparation and automated solutions. The company maintains a robust patent portfolio, supporting its ongoing research and development in both biological and solid-state nanopore technologies. Founded in 2005 and based in Oxford, United Kingdom, Oxford Nanopore Technologies also has offices in multiple countries, including the United States, China, and Germany.

Epicentre, is a manufacturer and seller of high-quality molecular biology products for life science research, clinical research, molecular diagnostics and biopharmaceutical manufacturing. Products are available for RNA amplification and gene expression analysis, transposon-based genetic analysis, DNA and RNA purification, DNA sequencing, PCR and RT-PCR amplification, DNA and RNA modifying enzymes, genomic cloning, in vitro transcription, and protein research and purification. In addition to our broad molecular biology product line, Epicentre also offers custom protein manufacturing.

Affomix is a biotechnology firm specializing in the development of antibody-based products, leveraging proprietary technology for the rapid and automated selection of human monoclonal antibodies (mAbs). The company focuses on commercializing its mAbs, mAb microarrays, and mAb libraries for a variety of applications, including research, drug discovery, diagnostics, and therapeutics. Affomix's innovative approach enables high-throughput production and screening of antibodies against a wide range of human proteins, including those that are post-translationally modified. This technology is particularly aimed at facilitating the sensitive and accurate measurement of numerous proteins in biological samples, thereby advancing the field of protein analysis and improving the efficacy of therapeutic solutions.

Helixis, Inc. is a company that develops low-cost molecular diagnostic products.

Oxford Nanopore Technologies Limited is a biotechnology company specializing in the development and commercialization of nanopore-based sequencing technology for the analysis of DNA, RNA, proteins, and small molecules. Its innovative product lineup includes the portable MinION device, the benchtop PromethION, and the GridION system, all of which enable real-time data streaming and scalable sequencing for a variety of applications in scientific research, personalized medicine, environmental monitoring, and agriculture. The Flongle offers smaller, on-demand sequencing solutions, catering to users requiring rapid insights. Operating in over 80 countries, Oxford Nanopore's technology is designed for accessibility and ease of use, featuring straightforward library preparation and automated solutions. The company maintains a robust patent portfolio, supporting its ongoing research and development in both biological and solid-state nanopore technologies. Founded in 2005 and based in Oxford, United Kingdom, Oxford Nanopore Technologies also has offices in multiple countries, including the United States, China, and Germany.

Oxford Nanopore Technologies Limited is a biotechnology company specializing in the development and commercialization of nanopore-based sequencing technology for the analysis of DNA, RNA, proteins, and small molecules. Its innovative product lineup includes the portable MinION device, the benchtop PromethION, and the GridION system, all of which enable real-time data streaming and scalable sequencing for a variety of applications in scientific research, personalized medicine, environmental monitoring, and agriculture. The Flongle offers smaller, on-demand sequencing solutions, catering to users requiring rapid insights. Operating in over 80 countries, Oxford Nanopore's technology is designed for accessibility and ease of use, featuring straightforward library preparation and automated solutions. The company maintains a robust patent portfolio, supporting its ongoing research and development in both biological and solid-state nanopore technologies. Founded in 2005 and based in Oxford, United Kingdom, Oxford Nanopore Technologies also has offices in multiple countries, including the United States, China, and Germany.

Solexa engages in developing and commercializing genetic analysis technologies primarily in the United States and the United Kingdom. The company is developing and preparing Solexa Genome Analysis System, which performs DNA sequencing based on its proprietary reversible terminator Sequencing-by-Synthesis, chemistry, and Clonal Single Molecule Array technology. Its platform is designed to support a range of analyses, including whole genome resequencing, gene expression analysis, and small RNA analysis.

Genizon Biosciences Inc. discovers genes and biomarkers in common diseases using genome wide association studies (GWAS), leveraging its proven and proprietary technology platform and access to patients from the Quebec Founder Population.

Pillar Biosciences develops next-generation sequencing based assays and software for NGS laboratories. It offers SLIMamp, a Stem-Loop Inhibition-Mediated amplification technology that enables specific priming of overlapping target segments, and PiVAT, an integrated bioinformatics analysis pipeline that produces an enhanced PBAM file for improved local realignment and read assembly. Founded in 2014, the company is headquartered in Natick, Massachusetts, with a presence in Shanghai, China. Its platform focuses on targeted sequencing to support treatment decisions in oncology, delivering high sensitivity and specificity for clinical samples. Pillar has released targeted panels such as Lung and Colon Cancer Somatic Mutation Panel and BRCA1/BRCA2 germline panels for validation by cancer centers and clinical testing companies in the US and China. The company emphasizes faster data delivery, lower costs, and broader access to localized diagnostics through its proprietary technology.